Novocure的电场癌症治疗显示,在胰腺癌试验中存活率提高。 Novocure's electric field cancer therapy shows improved survival rates in pancreatic cancer trial.

Novocure的肿瘤-治疗场(TTfields)疗法(TTfields)利用电场来瞄准癌症细胞,在对高级胰腺癌的第三阶段试验中显示出有希望的结果。 Novocure's Tumor-Treating Fields (TTFields) therapy, which uses electric fields to target cancer cells, has shown promising results in a Phase 3 trial for advanced pancreatic cancer. 与化疗相结合,它使总存活率中位数提高到16.20个月,而仅化疗就有14.16个月。 When combined with chemotherapy, it improved median overall survival to 16.20 months, compared to 14.16 months for chemotherapy alone. 治疗计划在美国、欧盟、日本和中国获得监管批准。 The therapy was well-tolerated and Novocure plans to seek regulatory approval in the U.S., EU, Japan, and China.